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Abstract 
Social innovation is viewed as a solution to developing new services that address complex 
needs and create 'social value' but what constitutes social value and how to measure it is 
contested. Drawing on an a case study of a social prescribing pilot, this paper provides an 
example of how social value can be evaluated to support decisions by commissioners of 
socially innovative interventions. It argues that social value presents an epistemological, and 
methodological challenge for commissioners seeking to embed it in decision making and 
recommends evaluating social innovations though a 'blended value' lens. 
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Introduction 
Social innovation, which addresses complex social problems and unmet needs through novel 
activities and services that maximise 'social value' (Phills et al, 2008; Mulgan et al, 2007), is 
increasingly seen by public policy makers as a solution to developing and testing new 
services (Mulgan et al, 2007). Its rise to prominence is closely linked to the austerity 
measures enacted by western governments following the 2008 global economic downturn 
and the predominance of neoliberal ideas and norms in western democracies which have 
led public bodies to seek market based approaches to service delivery that will reduce 
public sector costs and responsibilities (Eikenberry, 2009; Evans et al, 2005). However, the 
attention paid to social innovation also signifies a step-change in policy thinking which gives 
greater consideration to the wider social, economic and environmental benefits that accrue 
from public and social investment. This has historically been referred to as the 'triple 
bottom line' (Norman and MacDonald, 2004; Hubbard, 2009) and is increasingly identified in 
policy discourses as 'social value'. 
Despite its rise to prominence within policy discourses, the efficacy of different social 
innovations and policy makers' understanding of the scale and nature of the social value 
they create remains limited (Mulgan et al, 2007; Sinclair and Baglioni, 2014) and research 
and evaluation in the field lacks a conclusive definition and theoretical framework (Graddy-
Reed and Feldman, 2015). This paper contributes by considering what social value is and 
how it should be evaluated in the context of socially innovative services that have been 
funded by public sector bodies. Its central argument is that social value presents an 
epistemological and methodological challenge for commissioners, with the concept of 
'blended value' posited as offering a more holistic lens through which social value can be 
understood. Empirical support for this argument is provided through a case study of a 
socially innovative public service pilot, social prescribing, which was evaluated with the 
explicit intention of demonstrating its social value and provides an in-depth insight into the 
epistemological and methodological complexities of demonstrating social value when a 
wide array of social and economic benefits are evident for a number of different 
stakeholders. 
The paper begins by discussing the concepts of social innovation and social value and their 
position within mainstream policy making, focussing on some of the dominant narratives 
around how social value should be operationalised for commissioning purposes. It then 
presents empirical analysis of the social prescribing case study, discussing how the evidence 
contributes to an understanding of what social value is, in particular how it is 
operationalised and measured within public service commissioning.   
Social innovation and its relationship to social value 
Social innovation has been described as: 
"A novel solution to a social problem that is more effective, efficient, sustainable, or 
just than existing solutions and for which the value created accrues primarily to 
society as a whole rather than private individuals." (Philis et al, 2008, p 36) 
And: 
"Innovative activities and services that are motivated by the goal of meeting a social 
need and that are predominantly developed and diffused through organisations 
whose primary purposes are social." (Mulgan et al, 2007, p 8) 
Social innovations are typically developed in response to perceived market and government 
failures and it is argued that when markets (Philis et al, 2008), governments (Le Grand, 
1991; Wolf, 1979) and even traditional voluntary action (Salamon, 1987) fail social 
innovation is able to meet needs that would not be met through other means and create 
value that would not otherwise be created (Philis et al, 2008). Social innovations therefore 
tend to be created, adopted and diffused in a particular social and political context (Philis et 
al, 2008) or triggered as a response to a stimulus that could be internal to those involved or 
as a result of external pressures (Neumeier, 2012). 
The notion of additional 'social' value creation over private value creation is at the core of 
most conceptions of social innovation. Social value can be described as the benefits created 
for society through efforts to address social needs and problems (Philis et al, 2008): these 
benefits could be societal, economic or environmental and may accrue to disadvantaged 
groups in society or society as a whole but, crucially, they should go beyond the private gain 
and profit maximisation that motivates traditional market activity (ibid; Mulgan et al, 2007). 
Despite the absence of defining frameworks (Graddy-Reed and Feldman, 2015) most 
authors agree that social innovation occurs and its value takes effect beyond traditional 
market boundaries and as such is distinct from traditional business innovation. For example, 
Howaldt and Schwarz (2010) argue that social innovation does not occur in the medium of 
technical artefact but in social practice, while Neumeier (2012) emphasises the importance 
of sustainable social benefits arising from social innovation and Moulaert et al (2005) 
highlight the satisfaction of (social) needs that are not currently satisfied. This distinction 
between societal and private benefit is important as it provides a clear rationale for policy 
interventions that promote the development of social innovation and the creation of social 
value through publicly funded interventions (Borgaza and Bodini, 2014). 
Social innovation, social value and public sector policy 
Social innovations and the social value they have the potential to create resonate 
particularly strongly with the neo-liberal ideologies that dominate contemporary policy and 
politics. Since 2010 the UK and other western governments have implemented large scale 
public sector funding cuts and substantial programmes of welfare reform and public service 
transformation (Taylor-Gooby, 2012). Central to this is the stated intention to eliminate 
budget deficits and promote of market based approaches to service delivery that will reduce 
public sector costs and responsibilities (Eikenberry, 2009; Evans et al, 2005). Alongside these 
developments has been the emergence of a position in mainstream policymaking, 
sometimes referred to as public value governance, through which policy makers are 
encouraged to address effectively what the public most cares about and peruse what is 
good for the public through policy interventions (Moore, 1995 and 2013; Bryson et al, 2014). 
Although public sector funding cuts and marketisation have been extensively contested 
(Eikenberry, 2009; Taylor-Gooby, 2012), they are a reality and commissioners are drawn to 
social innovation because of its perceived ability to deliver a triumvirate of policy objectives 
in the form of competitively outsourced (i.e. cheaper) service provision, upstream savings to 
the public purse, and wider societal benefits (social value). 
In the UK, the drive to source market-based solutions for complex social problems in 
combination with wider social value benefits is encapsulated in the Public Services (Social 
Value) Act 2012. The Act requires that public authorities: i) have due regard to the 
economic, social and environmental well-being impacts of procuring public services, and; ii) 
must consider whether to consult on this issue at the pre-procurement stage. It applies to 
contracts across most parts of the public sector and was developed with the explicit aim of 
facilitating the growth of social enterprises, charities and cooperatives, and to have a 
positive impact in the areas where public services are commissioned. A note published 
alongside the Act clarifies that commissioners should "consider how what is to be procured 
may improve the social, environmental and economic well-being of the relevant area, and 
how they might secure any such improvement and consider the need to consult". 
The Act was initially heralded as important development in enabling more socially 
innovative organisations to engage in public service delivery. However, it does not make 
explicit reference to the commissioning and procurement steps that should be followed nor 
is it prescriptive about how social value should be interpreted in methodological or 
epistemological terms (Harlock, 2014; Teasdale et al, 2012). This lack of clarity raises some 
fundamental questions for commissioners about how social value should be measured. For 
example, should it be evidenced through quantitative indicators of economic or behavioural 
change; or should assessments be based on interpretive qualitative insights from different 
stakeholders in a service? In addition, should commissioners consider only the intended 
benefits of interventions, or include unintended or additional benefits, when considering 
social value? 
This uncertainty around social value is reflected in practice, where few policy led 
approaches to stimulating and measuring social value have been developed. Those that do 
exist, such as the social impact bond (SIB) funding mechanism (Fox et al, 2011) and the 
social return on investment (SROI) measurement framework (Millar and Hall, 2012; Nicholls 
et al, 2009), have been criticised for their emphasis on positivistic ͚ŵeĐhaŶiĐal͛ eĐoŶoŵiĐ 
models of cause and effect. These approaches tend to treat interventions in isolation, and 
attribute outcomes to them whilst failing to recognise the complexity and contexts of the 
social problems public services seek to address (McHugh et al, 2013). As a result, they tend 
to produce narrow or oversimplified understandings of social value with limited emphasis 
on the more intangible and unexpected benefits or the actual processes that contribute to 
social value (Arvidson et al, 2013; Harlock, 2014). 
In contrast to the positivistic approach to social value advocated by the SIB and SROI 
models, the 'blended value' approach to understanding social value provides a basis for 
capturing a broader series of benefits arising from a socially innovative service. Blended 
value was coined by Emerson (2003) and later developed by Nicholls (2009). It recognises 
that all organisations generate a combination of financial, economic and social outputs and 
outcomes and that these are intrinsically linked and should not be analysed in opposition 
through a zero-sum equation (Emerson, 2003; Nicholls, 2009). Using a blended value lens 
social value can be conceived as occurring on a spectrum that extends from quantitative 
understandings of financial or economic value at one pole to qualitative measures of social 
change on the other (Emerson, 2003). As such it provides and analytic methodology through 
which more effective operational responses to social problems can be designed (Nicholls, 
2009). As a loose epistemological framework it enables a social innovation such as social 
prescribing to be evaluated according to the different types of social value that accrue to 
different stakeholders. These stakeholder level distinctions are particularly important in the 
case of social innovation as Philis el at (2008) argue that innovation can only be considered 
truly social if it creates greater benefits to the public or society (particularly those facing 
disadvantage) as a whole (social value) than to investors and ordinary consumers (private 
value). Similarly, Neumeier (2012) suggests that the benefits arising from social innovation 
may well be manifested in changes in attitudes, behaviours or perceptions, in contrast to 
tangible economic benefits or technical improvements.  
The remainder of this paper aims to demonstrate the epistemological and methodological 
challenges of evaluating social value and how a blended value approach can be applied to 
develop a broader understanding of the benefits of socially innovative public services. It 
does this through a case study of social prescribing, a publicly funded social innovation pilot 
which was evaluated with the express intent of identifying the different types of social value 
created. 
Case Study: The social value of social prescribing 
This section provides the main empirical content of the paper, drawing extensively on 
quantitative and qualitative data collected and analysed for an evaluation of a social 
prescribing service, a social innovation pilot in community level health services. It begins 
with an introduction to social prescribing and the specific pilot being evaluated before 
presenting key insights and analysis from the evaluation, focussing on the operationalisation 
and measurement of social value within the commissioning process. 
An introduction to social prescribing 
Social prescribing is a catch-all term for non-medical services and referral pathways 
developed with the aim of preventing worsening health for people with long term health 
conditions and reducing the number and intensity of costly interventions in urgent or 
specialist care. In recent years a number of locality based social prescribing services have 
been developed by health and social care commissioners to provide a mechanism for 
General Practitioners (GPs) and other primary care services to link patients with sources of 
social, therapeutic and practical support provided by voluntary and community sector 
organisations in their locality. These social prescribing services have been developed in a 
policy environment which places greater emphasis on integrated preventative interventions 
for people from marginalised and disadvantaged groups (HM Government, 2010) alongside 
a pressure to reduce public sector budgets and implement market based approaches to 
delivery. The Department of Health (HM Government, 2006) has advocated social 
prescriptions for almost ten years whilst more recently NHS England (2014) has promoted 
non-clinical interventions from the voluntary and community sector as a way of making 
general practice more sustainable. 
The pilot on which this paper is based was one of the largest examples of social prescribing 
in the UK to date. It was funded by an NHS Clinical Commissioning Group (CCG) using £1 
million of non-recurrent monies that had not been committed for mainstream services. 
Local health commissioners had historically used non-recurrent funds to provide ad hoc 
grant funding for local voluntary and community organisations for small or short-term 
projects. The development of the social prescribing pilot was viewed as an opportunity to 
take a more sustainable and strategic approach to commissioning services that supported 
primary care objectives. As an NHS stakeholder explained: 
"(the local NHS CCG) were considering ways to make the voluntary sector more 
sustaiŶaďle…and around this time we were involved in discussions…aďout fuŶdiŶg a 
pilot project with the VCS as key players in supporting the NHS to address issues 
related to patients with long-term conditions" 
The pilot covered an entire local authority area, supporting more than 1,000 people with 
health conditions to access community level services over an 18 month period. A local 
voluntary sector organisation was commissioned to deliver the pilot, employing 'Advisors' 
whose role was to provide a link between the service and practitioners in primary and social 
care. The pilot also funded an additional 24 voluntary and community sector organisations 
through 'pump-priming' grants to deliver 31 separate 'micro-commissioned' services to 
complement existing local provision. Advisors received referrals from GPs of eligible patients 
and carers and assessed their support needs before referring them on to appropriate pump-
primed or wider voluntary and statutory provision. The assessment took place during a 
home visit where the Advisor would talk through the patient's needs and discuss the options 
available to them through social prescribing. Advisors also formed part of Inter-disciplinary 
Case Management Teams, attending meetings when social prescribing patients were being 
discussed where they fed back on the types of services accessed. 
The pilot can be considered an example of social innovation on a number of levels. First, at a 
programme level and similar to many examples of social innovation, the social prescribing 
pilot was developed as a response to a specific market failure (Philis et al, 2008): the myriad 
of information asymmetry and imperfect information that exists between people with long 
term conditions, health practitioners and commissioners, and providers (or potential 
providers) of community level services. Prior to the development of the pilot none of the 
parties had the requisite information for patients' needs to be met effectively. Second, and 
also at a programme level, the service delivery model was innovative compared to other 
social prescribing models in its provision of pump-priming grants, and in the way that micro 
service commissioning decisions related to these grants were devolved to a local voluntary 
organisation. Finally, and at community level, it was an example of 'grassroots innovation' in 
which networks of people and organisations organise themselves to generate novel 
solutions to social problems from the bottom-up (Seyfang and Smith, 2007). They differ 
from top-down approaches because the involve people and communities developing 
solutions for the betterment of the local area (ibid) in ways that build capacity and resilience 
(Kirwin at al, 2013). Pump-primed examples from the pilot include local neighbourhood 
groups developing peer-led sensory arts and crafts sessions for people suffering from social 
isolation and mental health problems, and peer advocacy support to enable women from 
BME communities to access to health services and social care packages. 
Social prescribing has been promoted by commissioners for it purported potential to create 
significant social value, including: better social and clinical outcomes for people with health 
conditions and their carers; more cost efficient and effective use of NHS and social care 
resources;  and a wider, more diverse and responsive local provider base. However, this 
position is based on commissioner's normative perceptions of social prescribing, rather than 
robust evidence, as there is limited good quality research or evaluation to inform the 
commissioning of social prescribing services, and most of the available evidence tends to 
describe small scale pilots with insufficient detail to judge success or value for money (Booth 
and Wilson, 2015). 
Operationalising and measuring the social value of social prescribing 
The normative social value 'proposition' described above provided the rationale for 
commissioning the social prescribing pilot on which this paper is based. However, service 
commissioners recognised the need for robust evidence if the pilot was to become 
embedded in mainstream provision in the longer term.  
"We want something robust to say this has stopped 200 people going into hospital". 
As such, the pilot was independently evaluated with the express intention of identifying the 
range of social value created, utilising the principles of the blended value approach, with a 
focus on the following social and economic benefits: 
 changes in the use of urgent and emergency hospital resources by patients referred to 
the pilot   changes in the well-being of patients referred to the services  any wider unintended changes for key stakeholders in the service 
 
Despite commissioner's interest in three broad areas of social value, and although their 
investment in social prescribing didn't displace funding for core NHS providers, they were 
quite clear that one measure - the reduction in the use of urgent and emergency hospital 
resources - would be given primacy in decisions regarding the re-commissioning or 
mainstreaming of the service.  
"From a commissioners point of view we’re (still) interested in the big picture, which 
is, if we spend x on a project designed to reduce acute admissions, have we saved x 
on acute admissions". 
As such, social value was operationalised through an evaluation methodology that provided 
them with sufficient evidence about the project's social value to make decisions about 
whether or not to extend their funding beyond the pilot period. Commissioners were kept 
up to date about the progress of the evaluation through an annual event where key 
progress measures were reviewed. 
The study utilised a mix of quantitative and qualitative data from a range of sources: 
hospital episodes data on a sample of social prescribing patients' use of hospital care were 
used to evidence resource impacts; a pre/post well-being questionnaire completed by social 
prescribing patients was used in conjunction with a series of qualitative interviews with 
patients and their carers (n=17) to understand well-being benefits; and qualitative 
interviews with commissioners (n=7) and providers (n=20) involved with the pilot provided 
evidence of wider benefits. Participation in the interviews was on the basis on informed 
consent, with ethical approval provided by the University Ethics Committee in addition to 
local NHS Research Governance approval to undertake a 'service evaluation'. 
The mixed-method multi-stakeholder approach enabled the evaluation to be framed within 
the blended value approach advocated by Emerson (2003) and Nicholls (2009) and produce 
a linked analysis of social and economic benefits rather than considering each separately or 
in opposition.  Information about each method is provided in the following sections, with an 
overview of their contribution to the evidence about social value provided in table 1. 
Analysis of the types of social value is presented in the sections that follow. 
<INSERT TABLE 1 AROUND HERE> 
Changes in the use of hospital resources 
For a cohort of 108 patients referred to the social prescribing service data was obtained 
from the NHS Data Management and Integration Centre (DMIC) on the number of inpatient 
stays, Accident and Emergency attendances, and outpatient appointments for the 12 month 
periods immediately prior to and following their first contact with the pilot. The sample 
included 42 patients who opted to take-up a social prescribing intervention with a pump-
primed provider and 66 patients who did not. These two groups of patients were compared 
to provide an indication of the effect of taking-up a 'social prescription'. 
 
The change in the number of hospital episodes for patients referred to social prescribing are 
presented in table 2. Data is presented for all patients referred to the social prescribing pilot 
alongside data for patients referred to pump-primed services and patients who did not take-
up a pump-primed service for comparative purposes. A related samples Wilcoxon Signed 
Rank Test score is provided as an indication of statistical significance: the data violated the 
assumption of normality required for a dependent t-test but the distribution of the 
differences between the two time points was symmetrically shaped, enabling a series of 
Wilcoxon tests to be performed. 
 
<INSERT TABLE 2 AROUND HERE> 
The data demonstrates a reduction in the number of each type of hospital episode following 
referral to social prescribing:  
  Inpatient admissions: there was an overall reduction of 21 per cent (0.30 per patient; 
p>0.05) in the number of admissions in the 12 month period following referral: patients 
referred to pump-primed services displayed a greater reduction (0.36 per patient; 
p>0.05) than those who did not take take-up a service (0.26 per patient; p>0.05) - a 
difference of 0.10 admissions per patient.  
  Accident and Emergency attendances: there was an overall reduction of 20 per cent 
(0.39 per patient; p>0.05) in the number of attendances in the 12 month period 
following referral: patients referred to a pump-primed service displayed a greater 
reduction (0.52 per patient; p>0.05) than those who did not take take-up a service (0.30 
per patient; p>0.05) - a difference of 0.22 attendances per patient. 
  Outpatient appointments: there was an overall reduction of 21 per cent (0.36 per 
patient; p>0.05) in the number of appointments in the 12 month period following 
referral: patients referred to a pump-primed service displayed a greater reduction (0.55 
per patient; p>0.05) than those who did not take take-up a service (0.24 per patient; 
p>0.05) - a difference of 0.31 appointments per patient.  
Despite these changes the results of the Wilcoxon Signed Rank Test indicate that the 
reductions observed cannot be considered statistically significant at 95 per cent confidence 
interval (p>0.05 in all three cases). This is likely to be due to the relatively small size of the 
sample (n=108) and the scale of the reductions identified. As such, the evaluation did not 
provide clear evidence that commissioners' primary social value target - to reduce use of 
urgent and emergency hospital resources - was being met within the timescales of the pilot. 
Changes in patient well-being 
A cohort of 280 social prescribing patients completed an eight-item five-point scale well-
being questionnaire at two points in time: at referral on their first contact with the pilot, 
and then four months later once they had engaged with pump-primed social prescribing 
services and were, in theory, expected to 'move on' to broader voluntary sector provision. 
The eight items covered by the questionnaire were developed to be indicative of an 
individual's ability to manage their long term condition more independently: feeling 
positive; lifestyle; looking after yourself; managing symptoms; work, volunteering and social 
groups; money; where you live; family and friends. Patients responded to a narrative 
description of each item with a score of between one and five (low to high) to describe how 
they felt 'today'. 
The mean baseline and follow-up scores for each measure on the well-being questionnaire 
are presented in table 3. The change in the mean score and the proportion making positive 
progress between the baseline and follow-up measurements is also presented. Overall, 83 
per cent of patients made progress on at least one outcome measure and each separate 
outcome measure demonstrated progress. In addition, the outcome measures with the 
lowest baseline scores exhibited the greatest amount of change: the mean score for 'work, 
volunteering and social groups' improved by 0.71 (2.52 to 3.23), with 49 per cent of patients 
demonstrating progress; similarly the mean score for 'feeling positive' improved by 0.43 
with 35 per cent of patients demonstrating progress.  
<INSERT TABLE 3 AROUND HERE> 
Analysis of outcome change for low-scoring patients provides an insight into the 
effectiveness of social prescribing at addressing patient's well-being in the areas where they 
exhibited most need. Tables 4-5 provide an overview of outcome change for patients who 
provided low-scores (two or less) in the baseline questionnaire. The mean baseline and 
follow-up scores for low-scoring patients for each measure is presented in table 4. The 
change in the mean score and the proportion making positive progress between the 
baseline and follow-up measurements is also presented. The proportion of patients 
providing a low score at baseline and follow-up stages is presented in table 5 along with a 
figure for the percentage point change and a Mcnemar test score to provide an indication of 
statistical significance.   
<INSERT TABLES 4-5 AROUND HERE> 
This demonstrates that compared to the full sample of patients, a greater degree of positive 
progress was exhibited against each outcome measure by low scoring patients and a higher 
proportion of low-scoring patients made positive progress. Similarly, for each outcome 
measure fewer patients provided a low score in the follow-up questionnaire than the 
baseline and the difference was statistically significant for seven of the eight measures. The 
only measure for which the change was not statistically significant was 'managing 
symptoms'. 
The survey evidence indicates that social prescribing was effective at helping patients 
achieve an immediate boost in their well-being, something which was corroborated by the 
findings from qualitative interviews, which identified well-being as one of the most 
important and widely identified benefits of the Pilot. Service providers were particularly 
effusive about the wide ranging well-being benefits they felt beneficiaries experienced and 
some specific examples of these benefits were identified through the interviews with 
patients and carers. Improvements in mental well-being were particularly evident: Mrs A 
welcomed the opportunity to meet people and interact by attending a sensory arts group, 
and saw is as a "lifeline" in her battle with anxiety and depression: 
 
"If it wasn’t for the group, I ŵight Ŷot ďe here Ŷoǁ ďeĐause I’d ďeeŶ that doǁŶ aŶd 
depressed….just gettiŶg out of the house has helped ŵe ǁith the fear, 
aŶǆietǇ…talkiŶg to people lifts Ǉour ŵood aŶd forget aďout proďleŵs at hoŵe".  
 
Similarly, Mrs B felt that attending a variety of groups and activities funded through the Pilot 
had "got her out of her depression" and Mrs C reflected that the activity she attended 
"ŵakes us feel ǁorthǇ iŶstead of ǁorthless…feeliŶg less depressed". 
 
A further benefit linked to beneficiaries' well-being was a reduction in social isolation and 
loneliness. Service providers highlighted the importance of linking people with limited 
mobility and social contact with the wider community and this was also evident in the 
interviews with beneficiaries. For eǆaŵple, ǁheŶ she ǁas referred Mrs C didŶ͛t eǆpeĐt to 
get anything out of Social Prescribing but has since realised that she now does not feel as 
isolated and was "just looking at four walls without the service" and noted "ǁhile Ǉou’re 
here you doŶ’t thiŶk aďout Ǉour health ĐoŶditioŶs, Ǉou just get oŶ ǁith it". Similarly, Mrs F, 
who received re-abling and befriending support through the pilot, valued the additional high 
quality social contact it provided. 
 
"It’s soŵeoŶe ĐoŵiŶg to talk to ŵe aŶd ǁith ŵe aŶd theǇ aĐkŶoǁledge ŵe…ďeĐause 
Ǉou ĐaŶ sit aŶd stare at spaĐe aŶd people take Ŷo ŶotiĐe ǁhatsoeǀer…I feel like I 
belong to a society". 
 
Increased independence was also identified by service providers and beneficiaries as an 
important benefit of Social Prescribing. In particular, those with limited mobility were able 
to become more independent as a result of improvements in their physical health. For 
example, Mr B had suffered a severe stroke three years ago, which affected his mobility and 
his speech, and was told his health may never improve. After being referred to social 
prescribing Mr B started going to a gym once a week, and participated in activities at the 
community centre on other days, including creative writing. Since receiving support through 
social prescribing Mr B had become more independent and positive. 
 
"I ǁas oŶ ŵǇ oǁŶ, I ǁas totallǇ oŶ ŵǇ oǁŶ…eaĐh daǇ I’ŵ gettiŶg ďetter aŶd 
ďetter…ďefore I Đould hardlǇ ǁalk…I’ŵ feeliŶg ǀerǇ positiǀe, eaĐh daǇ I get up aŶd I 
just ĐaŶ’t ďelieǀe hoǁ ŵuĐh I’ǀe Đoŵe oŶ". 
 
Similarly, Mrs G was referred to an exercise class and her mobility improved significantly. As 
a result she had "regained some independence", and felt better physically and emotionally 
because she had "something to look forward to". Without social prescribing, Mrs G believed 
she would withdraw within herself and become isolated again. 
Wider social value benefits 
In order to gain a broader perspective on the social value created by the social prescribing 
pilot the qualitative interviews explored how the social prescribing pilot had contributed to 
additional or unintended social or economic benefits from different stakeholder 
perspectives. Through these interviews it became clear that there was one important 
stakeholder group in receipt of benefits through the pilot who had not been considered by 
commissioners through their original conception of social value: the local voluntary and 
community sector, both organisations in receipt of pump-priming grants and the wider body 
of groups and organisations within the locality.  
For many of the 24 voluntary and community sector organisations in receipt of pump-
priming grants the pilot was the first time they had been in receipt of statutory health 
funding. As such, for the first time these organisations were able to demonstrate to 
commissioners their ability to contribute to local strategic health and well-being targets and 
outcomes. As one VCS provider explained "previously, advocacy work (now being funded 
through social prescribing) was unpaid (unfunded)" and the pump-priming grant had 
enabled them to expand the service and receive referrals from health professionals that had 
not been possible prior to the pilot. These organisations were also able to add considerable 
value to the social prescribing pilot by cross-referring patients to other services they 
provided or that were provided by partner organisations. 
 ";The orgaŶisatioŶͿ also proǀides other serǀiĐes ;that ĐaŶ ďe aĐĐessedͿ…a ǁelfare 
advisor, who can provide benefit checks and other information for patients. We also 
have relatioŶships ǁith other orgaŶisatioŶs…so ĐaŶ take shortĐuts iŶ fiŶdiŶg help for 
patients." 
A further, unexpected benefit for a number of voluntary and community organisations, and 
by extension the local people they supported, was the ability to use social prescribing to 
attract additional income from other sources. Three voluntary and community organisations 
in receipt of pump-priming grants were able to secure additional grant funding as a result of 
their social prescribing work: one provider received £180,000 from the Big Lottery Fund 
(BLF), one received £10,000 from NHS England and another received £10,000 from Awards 
for All (BLF small grants fund). In addition, 11 pump-primed providers reported that social 
prescribing patients had accessed additional services though self-funding or by using their 
Direct Payments or Personal Budgets: the value of this additional income was at least 
£10,000 over the course of the pilot. 
Beyond those voluntary and community organisations in receipt of pump-priming grants 
there were a number of examples of beneficiaries becoming involved in independent social 
and community action since accessing services pump-primed through the pilot. This includes 
patients becoming volunteers within the organisations they were referred to, establishing 
new peer and interest groups based on the principles of self-help and mutual aid, and 
accessing services in the wider voluntary and community sector that were not directly part 
of the social prescribing pilot. For these individuals social prescribing provided a necessary 
first step in their involvement in and engagement with wider voluntary and community 
activity. 
 
Case study epilogue: onward commissioning of the social prescribing pilot 
 
It is important to conclude discussion of the social prescribing case study with a note on 
what happened with the service upon conclusion of the pilot. In short, it was re-
commissioned for a further three years with the same level of resource as part of the local 
health and social care integration programme. Although the evaluation was not able to 
evidence significant reductions in urgent and emergency hospital attendances 
commissioners viewed the findings as demonstrating a positive indication of effectiveness. 
Importantly, they were also swayed by the breadth of evidence available on the wider social 
value benefits of social prescribing; in particular the narrative qualitative accounts provided 
by patients and GPs on the wider impacts of the pilot. 
 
"It was interesting that when the lead from the CCG was initially putting together the 
eǀideŶĐe oŶ Đase ŵaŶageŵeŶt…he seeŵed a little sĐeptiĐal aďout social prescribing 
but the overwhelming positive feedback from the GPs involved in the presentation 
convinced him to put a lot more emphasis in about it.  GPs also spoke up in favour of 
social prescribing following our presentation at the Commissioning Event, which I 




This paper has used a local level case study of a social prescribing pilot to demonstrate how 
the concept of social value can be operationalised for evaluation purposes in the context of 
socially innovative services commissioned by public sector bodies. This concluding section 
reflects on the case study evidence presented to consider the implications for evaluators 
and commissioners interested in understanding the social value of social innovation, and 
presents an argument for wider utilisation of blended value approaches to overcome the 
epistemological and methodological challenges involved. 
The social prescribing case study highlights the central role commissioners play in 
determining what constitutes social value in the services they develop and procure. This role 
is enshrined in law through the Public Services (Social Value) Act and is likely to grow in 
importance as more public services are outsourced to the voluntary and community sector. 
The case study also demonstrates how commissioner's conceptions of social value can tend 
towards narrow, positivistic quantitative measures of change (Arvidson et al, 2013; Harlock, 
2014) with an emphasis on resource utilisation that might lead to 'cashable' savings in the 
longer term. This is understandable in the context of severe public sector budget cuts 
(Taylor-Gooby, 2012) and the predominance of neoliberal led ideologies that prioritise 
reducing public sector costs and responsibilities (Eikenberry, 2009; Evans et al, 2005). 
However, the literature on social innovation and social value discussed at the beginning of 
this paper emphasises that social value is a complex multi-stakeholder phenomena and 
evaluation of  it ought to reflect a plurality of stakeholder perspectives. The principle of 
incorporating multi-stakeholder perspectives in an understanding social value is 
encapsulated by the blended value approach embedded in the evaluation of the social 
prescribing pilot and the benefits identified as accruing to local voluntary and community 
organisations are a clear example of how a multi-stakeholder approach can unearth 
evidence that would have not have been identified if a narrow definition of social value had 
been adhered to. 
Applying a mixture of qualitative and quantitative methods, as appropriate, is a further 
feature of the blended value approach and the case study has demonstrated how holistic 
evaluation into the multi-stakeholder social value benefits of social innovation can be 
undertaken in this way. Although the Hospital Episodes Statistics did not provide statistically 
significant evidence of a reduction in urgent and emergency care use the qualitative 
interviews with social prescribing patients provided a range of examples of how people's 
health and mental health improved following a social prescribing intervention. Similarly, the 
well-being survey findings were corroborated by examples from the qualitative interviews 
and provided reassurance that genuine and important well-being improvements had 
occurred whilst the evidence about the benefits accruing to local voluntary and community 
organisations would not have been surfaced without the use of qualitative research. It was 
this broader blended value evidence base that convinced commissioners to continue 
funding the pilot rather than a single social value benefit for a narrowly defined stakeholder 
group. 
In moving away from a zero-sum understanding of the social value of the social prescribing 
pilot based on evidence of an immediate reduction in urgent and emergency care use the 
commissioners demonstrated a step-change in their epistemological understanding and 
expectations of social value. Their  incorporation of a broader range of blended value 
evidence into their social value 'equation' signified a realisation that socially innovative 
projects can be positively or adversely affected by strengths or limitations in other parts of 
the support system that a particular target group needs for a positive outcome to occur 
(Pawson, 2002). Similarly, they recognised that direct attribution of an outcome to a specific 
intervention is not always possible when its effect could be due to other services or an 
improvement in the wider environment (such as the economy) (McHugh et al, 2013). In fact, 
Hall (2002) reminds us that the underlying causes of outcomes are rarely known to policy 
managers and Bovaird (2014) argues that over many years cause-and-effect analysis in 
policy development making has been inconsistently applied and poorly understood. In this 
context it is important for commissioners to utilise a range of evidence from a variety of 
sources when operationalising and measuring social value.  
 
The social prescribing case study provides an example of the underlying dual purpose to the 
measurement and communication of social value: although demonstrating progress against 
a series of social value aims and objectives is important, particularly in the context of public 
service commissioning, social value evidence also serves as an important communicative 
and discursive device. Throughout the social prescribing pilot commissioners and service 
providers maintained a regular dialogue regarding progress towards agreed social value 
objectives. This process enabled the blended value evidence to be introduced and raised 
commissioners' awareness of the wider benefits of the services they had funded. The 
ongoing dialogue about social value created a situation in which commissioners where able 
to make an epistemological step-change in their understanding of what counts as 'valid' 
evidence and be convinced of the importance of including qualitative evidence in 
combination with quantitative evidence in their social value equation. By assigning equal 
weight to the different types of evidence collected commissioners developed a broader 
understanding of the social value created through the pilot that would not have been 
possible if the initial narrow definition of social value had been adhered to. Commissioners 
of socially innovative public services are therefore recommended to apply a blended value 
approach to social value evaluation if they are to develop a full and rounded understanding 
of the social and economic benefits of the interventions being delivered. 
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Tables and Figures 
Table 1: Overview of social value methodology 
 Type of Social Value Benefit 
Hospital Resources Well-being Wider/Unintended 
Hospital episodes data x   
Well-being questionnaire  x x 
Qualitative interviews  x x 
Table 2: Change in number of hospital inpatient admissions 
 
All patients referred to Social Prescribing 













Non-elective inpatient admissions: 
All patients referred to Social Prescribing  1.46 1.17 -0.30 -20.5 0.229 108 
Patients referred to pump primed services 1.45 1.10 -0.36 -24.8 0.155 42 
Patients who did not take-up a pump 
primed service 
1.47 1.21 -0.26 -17.5 0.607 66 
A and E attendances: 
All patients referred to Social Prescribing  1.94 1.56 -0.39 -20.1 0.169 108 
Patients referred to pump primed services 2.19 1.67 -0.52 -23.7 0.088 42 
Patients who did not take-up a pump 
primed service 
1.79 1.48 -0.30 -16.9 0.768 66 
Outpatient appointments: 
All patients referred to Social Prescribing  1.70 1.34 -0.36 -21.2 0.079 108 
Patients referred to pump primed services 1.90 1.36 -0.55 -28.9 0.203 42 
Patients who did not take-up a pump 
primed service 
1.58 1.33 -0.24 -15.4 0.229 66 
Base: 108 patients referred to social prescribing pilot 
Note that the figures presented will not always sum precisely due to rounding 
 









Positive progress made 
n Per cent 
Feeling positive 3.21 3.63 0.43 97 35 
Lifestyle 3.58 3.84 0.26 69 25 
Looking after yourself 3.69 3.94 0.24 68 24 
Managing symptoms 3.52 3.66 0.14 60 21 
Work, volunteering and social groups 2.52 3.23 0.71 136 49 
Money 4.13 4.43 0.31 59 21 
Where you live 4.15 4.45 0.31 57 20 
Family and friends 3.55 3.87 0.31 76 27 
Base: 280 patients referred to pump primed social prescribing services 
Note that the figures presented will not always sum precisely due to rounding 
 










Positive progress made 
n Per cent 
Feeling positive 70 1.71 2.77 1.06 43 61 
Lifestyle 45 1.67 2.69 1.02 29 64 
Looking after yourself 35 1.66 2.74 1.09 21 60 
Managing symptoms 44 1.68 2.70 1.02 25 57 
Work, volunteering and social 
groups 
119 1.55 2.70 1.15 64 54 
Money 25 1.68 3.33 1.65 19 76 
Where you live 18 1.56 3.41 1.86 14 78 
Family and friends 35 1.66 2.94 1.29 24 69 
Base: Patients referred to pump primed social prescribing services with low baseline scores (2 or less).  
Note that the figures presented will not always sum precisely due to rounding 
 
Table 5: Change in health and well-being outcome measures: percentage of respondents recording 













Feeling positive 70 25 36 13 -12 p<0.001 
Lifestyle 45 16 29 10 -6 p<0.01 
Looking after yourself 35 13 20 7 -5 p<0.01 
Managing symptoms 44 16 35 13 -3 p>0.05 
Work, volunteering and social 
groups 
119 43 68 24 -18 p<0.001 
Money 25 9 7 3 -6 p<0.001 
Where you live 18 6 4 1 -5 p<0.01 
Family and friends 35 13 20 7 -5 p<0.01 
Base: 280 patients referred to pump primed social prescribing services 
Note that the figures presented will not always sum precisely due to rounding 
